Generic selectors
Exact matches only
Search in title
Search in content
Get in touch

Biotechnology

The Biotechnology team at KTN focuses on Industrial Biotechnology (IB), Engineering Biology (EB, commonly referred to as Synthetic Biology) and Microbiomes.

Biotechnology

These technologies have the potential to carry out transformations which would not be feasible, technically or economically, using traditional chemistry. They hold the potential to make entirely new materials or to develop processes which run at low or ambient temperatures, thus reducing energy consumption. Consequently they can have a major impact in the UK’s move to Net Zero emissions.

The team works with all sectors that either use, or are interested in using, biotechnology in their business, in particular Chemicals, Pharmaceuticals, Home & Personal Care, AgroChemicals, Food and Drink – and many more.

Our experts use deep knowledge of the sector to help you and your business innovate through access to funding, expertise and building connections and collaborations. The team works closely with national bodies such as the Industrial Biotechnology Leadership Forum (IBLF) and the Engineering Biology Leadership Council (EBLC). They have developed landscape maps for Industrial Biology and Engineering Biology to enable users to find potential partners and collaborators in the UK.

Follow us on Twitter: @KTN_Biotech

Our current focus in this area

Engineering Biology

Engineering Biology (EngBio) provides us with the opportunity to step away from traditional methods and provide innovative solutions for challenges brought by climate change and the associated impact areas, like food availability and the need for sustainable feedstocks.

Industrial Biotechnology

Similar to Engineering Biology, Industrial Biotech impacts numerous sectors including Chemistry, Materials, Healthcare and AgriFood. It also has a significant role in the development of a Circular Economy by using waste as a feedstock for biobased products.

Microbiome

The Microbiome Innovation Network (formerly SIG) aims to accelerate the commercialisation of microbiome-based products and services in the UK and create a vibrant community by connecting industry and academia.

Funding Opportunities

Biomedical Catalyst 2022 Round 1: Industry-led R&D

UK registered SMEs can apply for a share of up to £15 million to develop innovative solutions to health and healthcare challenges.

Opens: 28/03/2022 Closes: 25/05/2022

Explore Further

Innovation Loans Future Economy Competition – Round 2

UK registered businesses can apply for loans for innovative projects with strong commercial potential to significantly improve the UK economy.

Opens: 14/04/2022 Closes: 11/05/2022

Explore Further

Innovate UK Smart Grants: April 2022

UK registered organisations can apply for a share of up to £25 million for game-changing, commercially viable R&D innovation that can significantly impact the UK economy. It must be an innovative, disruptive, ambitious, world-class solution, with no similar technology commercially available anywhere in the world.

Opens: 25/04/2022 Closes: 27/07/2022

Explore Further

Events

Thu
24
Feb
2022

Approaches to Life Cycle Assessment in the Bioeconomy

10.00 - 11.30 | Online

Watch Now

Tue
22
Mar
2022

InSilicoUK network launch

13.30 - 17.00 | Online

Watch now

Thu
5
May
2022

Transforming local bio-based waste streams into circular textile and building materials

10.00 - 12.00 | Online

Watch Now

News

21.03.2022

HydroGenerally Podcast Series

The Hydrogen Economy Innovation Network is delighted to share with you: HydroGenerally – a podcast series that is giving a voice to explore the applications, opportunities and challenges of the hydrogen economy, in a series of 20-minute discussions led by Innovate UK KTN’s experts in Hydrogen, Steffan Eldred and Simon Buckley.

Read more

10.03.2022

Sustainable aviation fuels mandate - Summary of consultation responses

The Department for Transport has published their summary of responses to the Mandating the use of sustainable aviation fuels in the UK consultation.

Read more